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Use of a new phosphate binder in chronic renal insufficiency.
The role of phosphorus retention in the development of second-
ary hyperparathyroidism in renal failure is well established. Un-
fortunately, there are no nutritionally complete, palatable, low-
phosphorus diets. Thus, phosphorus-binding gels have been pre-
scribed to control phosphorus absorption from the gastrointesti-
nal tract. Most of these binders are aluminum-containing prepa-
rations designed to be used as antacids and, as such, were not
optimized for high anion binding capacity. We have prepared a
new phosphorus binder, an aluminum oxide-based gel, with an
increased anion binding capacity. This material (ControphosTM)
was incorporated into breadsticks in order to increase patient
tolerance. Toxicologic studies performed in rats indicated that
the animals ingesting this experimental binder did not show in-
creased aluminum concentration in the brain. Metabolic studies
in which oxygen consumption was determined in cortical renal
slices suggested that a decrease in oxygen consumption was due
to phosphate deficiency and not to the binder itself. Studies in
dialysis patients clearly demonstrated that hyperphosphatemia
can be easily corrected. Moreover, balance studies in patients
with chronic renal failure indicated that this experimental binder
incorporated into breadsticks is as effective as the best available
phosphorus binder (aluminum carbonate gel, Basaijel®). When
aluminum carbonate gel, however, was incorporated into
breadsticks, its capacity to bind phosphorus was greatly re-
duced. Summary. A new phosphorus binder that retains high
binding capacity even when incorporated into breadsticks was
well accepted and tolerated by patients with chronic renal fail-
ure.
Emploi d'un nouveau chélateur du phosphore dans
l'insuffisance rénale chronique Le role de Ia retention de phos-
phore dans Ic développement de l'hyperparathyroIdisme second-
aire de l'insuffisance rénale est bien établi. Malheureusement il
n'existe pas de regimes pauvres en phosphate complets du point
de vue nutritionnel et de gout agreable. Par consequent les gels
qui se combinent au phosphore ont été prescrits pour en limiter
l'absorption digestive. La plupart de ces substances contiennent
d'aluminium, qui a une capacité de liaison aux anions accrue.
Cette substance (ControphosTM) a été incorporée a des gressins
pour en augmenter Ia tolerance. Les etudes toxicologiques
réalisées chez le rat indiquent que les animaux qui ingérent cette
substance n'ont pas d'augmentation de Ia concentration céré-
brale d'aluminium. Les etudes métaboliques dan lesquelles Ia
consommation d'oxygéne de tranches de cortex renal a été
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déterminée suggèrent que Ia diminution de cette consommation
est due au deficit du phosphate et non a Ia substance elle-
méme. Les etudes faites chez des malades en dialyse dCmont-
rent que l'hyperphosphatemie peut étre facilement corrigee. Les
etudes de bilan chez des malades en insuffisance rénale chro-
nique indiquent que cette substance incorporée dans des gressins
est aussi efficace que Ic meilleur produit jusque là disponible
(gel de carbonate d'aluminium, Basaljel®). Cependant quand ce
gel a été incorporé dans des gressins, sa capacité a her Ic phos-
phore a été considérablement réduite. En résumé, un nouveau
chélateur du phosphore, qui conserve sa grande capacité quand
ii est incorporé a des gressins, a été bien accepté et supporté
par des malades en insuffisance rénale chronique.
The role of phosphorus retention in the develop-
ment of secondary hyperparathyroidism in chronic
renal disease is well established [1]. If phosphorus
absorption is decreased, however, in direct propor-
tion to the decrease in renal function, hyper-
parathyroidism and its adverse effects can be pre-
vented [2, 3]. There is also evidence to suggest that
phosphorus retention interferes with vitamin D me-
tabolism by decreasing the conversion of 25(OH)D3
to 1 ,25(OH)2D3 14]. Moreover, phosphate retention
also may play a role in the development of skeletal
resistance in the rat with acute renal failure [5]. For
all these reasons, the control of the intestinal ab-
sorption of phosphorus is important to the patient
with compromised renal function. Unfortunately,
there are no nutritionally complete, palatable, low-
phosphorus diets. Consequently, phosphorus-bind-
ing gels have been prescribed with food to control
phosphorus absorption in order to prevent second-
ary hyperparathyroidism while continuing to pro-
vide adequate nutrition. The most effective phos-
phorus-binding agents are poorly soluble, alumi-
flu rn-containing gels. Unfortunately, many patients
find them distasteful, and many suffer from nausea
and vomiting following ingestion. Most of these
standard aluminum-containing preparations were
designed for use as antacids and, as such, were not
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optimized for high anion-binding capacity. The ani-
on binding capacity of aluminum hydroxide can be
increased by forming the gels at low pH. Such a gel,
ControphosTM (an aluminum oxide-based gel), was
prepared and found to have the highest phosphorus-
binding capacity of any available gel both in vitro
and in vivo in the dog [6]. This material was incor-
porated into breadsticks in order to increase patient
tolerance.
Another obstacle to treatment with aluminum-
containing gels is the potential development of
aluminum toxicity. There is substantial evidence
that the administration of large quantities of alumi-
num may be fatal to the rat if given orally as soluble
aluminum salts or parenterally as poorly soluble
aluminum gels [7, 8]. The same group that reported
these findings also noticed decreased oxygen con-
sumption by the liver of rats treated with aluminum.
The possibility of aluminum toxicity in humans as
a consequence of antacid ingestion has been raised
by Alfrey. Le Gendre, and Kaehny [9], who de-
scribed a fatal encephalopathic syndrome in dialysis
patients who were subsequently found to have high
concentrations of aluminum in their brains [9]. It is
clear that aluminum does accumulate in the brain of
some dialyzed patients. It is not clear in patients
with renal failure whether aluminum gains access to
body tissues from the gastrointestinal tract or from
the dialysate; the latter source, however, appears to
be more significant [10, 11].
There are no toxic materials used in the manufac-
ture of the new gel, and its solubility has been found
to be lower than that of commercially available gels.
As a safety measure, however, toxicity studies
were performed in the rat prior to its administration
to patients.
Methods
Gel preparation. The new gel (ControphosTM) re-
ported in this paper was formed at a final pH of 5.7
by partial neutralization of aluminum sulfate solu-
tion with ammonium hydroxide. The gel was then
centrifuged and washed. Before the gel was used as
a phosphorus binder, the undesirable sulfate ions
were replaced by acetate, using ion exchange.
Rat toxicity studies. Female Holtzman rats, each
weighing approximately 200 g, were used for this
study. Uremia was induced surgically by infarcting
50% to 70% of one kidney and performing a con-
tralateral nephrectomy. Tube-feeding was started 2
weeks after surgery according to the diet schedule
listed in Table 1. The amount of gel, Basaljel®
(aluminum carbonate gel) or Controphos, adminis-
tered was equal on a dry weight basis. For refer-
ence, the amount of Basaljel fed each rat was equiv-
alent to the daily administration of 1.3 liters of liq-
uid Basaljel to a 70-kg man.
After 1 month, the animals were lightly anesthe-
tized with ether and sacrificed by decapitation. The
renal cortex was sliced and incubated in a physio-
logic solution buffered with 10 mrvi Tris, 5 mrvi glu-
cose, and 0.5 mi glutamine, as previously de-
scribed [12]. Oxygen consumption was measured in
a Gilson differential respirometer, as previously de-
scribed [12].
Approximately 100 mg each of rat brain (cortical
gray and white matter) were homogenized separate-
ly in 1 cc of a saturated solution of EDTA. The
whole homogenate was frozen and stored at —80° C
in plastic scintillation vials. At the time of assay the
homogenate was thawed and mixed well prior to an-
alyzing for aluminum.
Alu,ninu,n assay. All water used for preparation
of standards, dilution of samples, and washing of
glassware was doubly deionized and had a resis-
tance of 5 megaohms. Redistilled nitric acid (G.
Frederick Smith Chemical Co., Columbus, Ohio)
was used throughout. All glassware was decontami-
nated with two digestions of concentrated nitric
acid and rinsed ten times with deionized water be-
tween each digestion. Plastic scintillation vials were
used for sample storage after rinsing three times
with dilute nitric acid (10 mllliter).
Table 1. Chemical composition of the diets fed to four groups of rats
Group Group Group Group
Dieta I II III IV
Fibrindiet,g/day 9.6 9.6 9.6 9.6
Fibrin diet + P. mg/day 164 164 164 439
Fibrin diet + Basaijel®, mi/day — 4 — —
Fibrin diet + ControphosTM, mg/day — — 496 496
Fibrin diet is a low-phosphorus diet (Nutritional Biochemical Company).
The quantity of ControphosTM given was calculated on the basis of a phosphorus-binding capacity equivalent to that of liquid Basal-
jel®, which is also approximately the aluminum content of Basaijel®. The equivalent phosphorus-binding capacity was based on
previous in vitro and in vivo studies [6].
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Standard solutions of aluminum were freshly pre-
pared each week and carefully checked at each ana-
lytical run for constancy of absorption in the con-
centration range of 20 to 300 sg/1iter from a 1000-
mg/literreference standard (Fisher Scientific Co.) in
dilute (10 mllliter) nitric acid.
Aluminum assay was performed with an atomic
absorption spectrophotometer (model 403) with at-
tached deuterium arc for background correction.
The absorption peaks were recorded with a record-
er (model 165, Perkin Elmer Corp., Norwalk, Con-
necticut). Twenty microliters of the whole homoge-
nate was transferred to a standard graphite tube
with an Oxford pipet. Optimum temperature and
time for drying, charring, and atomizing was estab-
lished experimentally. Drying was set for 40 sec at
285° C, and the temperature was slowly raised to
600° C after 30 sec. Charring was carried out at
1500° C for 30 sec, and atomizing at 2600° C for 8
sec. The chamber was purged with argon. The fur-
nace was operated in the "interrupt" mode, so that
the flow of purge gas to the furnace was stopped
during the atomization step. A series of aluminum
standards in nitric acid (10 mllliter) was analyzed in
the same manner, and a standard curve obtained.
All reagents used in sample collection and prepara-
tion were carried through in the blank which consis-
tently corresponded to 10 pg/liter.
Human studies. Two groups of patients were
studied. The first group included six (pts A to F) of
our most reliable and compliant patients undergoing
regular hemodialysis. The patients were dialyzed
three times per week, and blood was obtained for
phosphorus determination immediately prior to
each dialysis. There were three periods during
which time the patients ingested their usual diets as
outpatients plus the following: (1) 8 Basaijel cap-
sules/day for 2 weeks, (2) no phosphorus binding
gels for 2 weeks, (3) 4 Controphos breadsticks
per day for 2 weeks (the amount of gel in each
breadstick was equal to two Basaljel capsules on a
dry weight basis). The breadsticks were prepared
by the Doyle Pharmaceutical Company, Division of
Delmark, Inc.
The second group consisted of four patients
(Table 2) with chronic stable renal disease who
were admitted to the Washington University Clini-
cal Research Center for balance studies. A dietary
history was obtained, and they were fed a diet ap-
proximating their usual intake. The phosphorus in-
gestion for the group varied from 1040 to 1729 mg/
day. Two diets were prepared for each patient, and
they were ingested on alternate days.
Table 2. Clinical data in four patients with chronic renal failure
Patient
Age
yr Diagnosis
GFR
mi/mm
1 39 Nephrocalcinosis 44.8
2 40 Glomeruloscierosis 25.3
3 65 Glomerulosclerosis 41.7
4 42 Pyelonephritis 6.9
Each study lasted 64 days and was divided into
two 32-day periods. No gel was administered during
the first 16 days (control) of each period, and the
gels (Basaljel or Controphos) were administered
during the last 16 days. A minimum of 2 weeks sep-
arated each 32-day study period. Controphos gel
was administered in breadsticks: one with break-
fast, one with lunch, and two with the evening meal.
Basaljel was administered as capsules: two with
breakfast, three each with lunch and the evening
meal. All urine was collected; phosphorus and
creatinine concentrations were measured daily [1,
2], and stools were collected in 4-day pools and ana-
lyzed for phosphorus as previously described [13].
Blood was drawn twice during each control and ex-
perimental period for the following determinations:
complete blood count, platelet count, prothrombin
time, partial thromboplastin time, serum glutamic
oxaloacetic transaminase, serum glutamic pyruvic
transaminase, lactic dehydrogenase, bilirubin, total
protein, albumin, uric acid, cholesterol, blood sug-
ar, and electrolytes. Blood was drawn every other
day for the measurement of serum creatinine and
phosphorus [1].
Dog studies. Previous studies in the dog [6] dem-
onstrated that Controphos had a higher phos-
phorus-binding capacity than did Basaljel; the gels
that were administered, however, had not been in-
corporated (baked) into breadsticks. The following
study was performed to determine the relative in
vivo phosphorus-binding capacity of these two gels
after being baked into breadsticks. Four dogs were
given 30 mg of phosphorus (liquid neutral sodium
salt) per kilogram of body weight by nasogastric
tube on three separate occasions 1 week apart, as
follows: (1) 10 g of breadsticks containing no gel
(control) with phosphorus; (2) standard phosphate
load with Controphos baked into breadsticks; (3)
standard phosphorus load with Basaljel (a quantity
equal to two capsules) baked into breadsticks. The
quantity of the new gel was equal to Basaljel on a
dry weight basis.
Phosphorus was measured by methods pre-
viously described [1, 2] on serum and urine ob-
tained hourly for 5 hours. Previous studies demon-
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strated that a phosphorus load of this magnitude
was excreted in the urine within 5 hours in animals
with normal renal function and intact parathyroid
glands [6]. Thus, the 5-hour excretion of phos-
phorus serves as an indirect assessment of phos-
phorus absorption from the gastrointestinal tract.
Results
Rat toxicity studies. The concentration of alumi-
num in brain of normal and uremic rats is shown in
Table 3. There were no differences in the aluminum
concentration of brain between normal and uremic
animals, and no significant differences between con-
trol rats and those given aluminum-containing gels
were noted.
The serum phosphorus concentrations are shown
in Table 4. The highest mean concentrations were
found in the control uremic group (group I) and the
uremic group given Controphos gel plus extra phos-
phorus (group IV).
The results of oxygen consumption by renal cor-
tex slices are shown in Table 5. Renal oxygen con-
sumption of control uremic rats (18.9 p1/mg dry wt/
hr) was significantly greater than that of normal
controls (15.2 p.11mg dry wt/hr). Oxygen consump-
tion by kidney slices from normal and uremic ani-
mals fed aluminum-containing gels (groups II and
III) were, however, significantly lower than that of
control animals, except for the last group (IV) which
was given the Controphos gel plus a surfeit of phos-
phorus. Oxygen consumption by kidneys of this last
group (IV) was not significantly different from that
of control animals (group I).
Table 3. Aluminum concentrations in rat braina
Brain aluminum, p.glg ii'et lit
PNormal Uremic
Control 0.43 0.06 0.51 0.13
ControphosTM 0.46 0.12 0.28 0.04
Basaljel® 0.44 0.10 0.42 0.11
NS
NS
NS
a Values are the means SEM.
Table 4. Serum phosphorus concentration in ratsa
Serum phosphorus, ing/dI
PGroup Normal Uremic
I 5.55 0.43 10.54 2.91
II 5.99 0.56 4.63 0.40
III 5.55 0.18 4.75 0.37
IV 5.67 0.46 7.27 1.16
<0.05
NS
NS
NS
a Values are the means SEM.
Groups are defined as follows: I, control; II, Basalgel® thera-
py; III, ControphosTM therapy; IV, Controphos plus phosphorus.
Human studies. The results of the serum phos-
phorus measurements in the group of outpatients (A
to F) undergoing chronic hemodialysis are shown in
Table 6. Both gels lowered the mean serum phos-
phorus concentration significantly, but the lowest
mean phosphorus concentration was observed dur-
ing treatment with breadsticks containing Con-
trophos. The results obtained in a patient fed a strict
phosphorus diet are shown in Fig. 1. In patient 1,
there was an average decrease of 306 mg of phos-
phorus in the urine and an increase of 385 mg of
phosphorus in the feces while taking the bread-
sticks. There was an average decrease of 204 mg of
phosphorus in the urine while taking Basaljel. The
mean values for all four patients are shown in Fig.
2. Overall, the gels were of equal efficacy, and the
mean decrease in urine phosphorus was about the
same as the increase in fecal phosphorus content for
the group.
Dog studies. The results of the change in serum
phosphorus concentration in dogs receiving phos-
phorus, with and without gels, are shown in Fig. 3.
The maximum change occurred 2 hours after the
oral load. The mean change in concentration during
the control study was 2.82 0.66 mg/dl. It was 1.84
0.112 mgldl when Basaljel was given and 1.07
0.13 mg/dl when Controphos was given. Each mean
is significantly different from the other. The quanti-
ty of phosphorus excreted in the urine over a 5-hour
period is shown in Fig. 4 plotted as a percent of the
Table 5. 0xygen consumption in rat renal cortexa
Group
Oxygen consumption, 1/ing dr' nt/hr
Normal Uremic
I
II
Ifl
IV
15.24 0.64 (N =
13.18 0.53 (N =
12.61 056b (N =
16.52 0.97 (N =
37) 18.91 0.94 (N = 19)
29) 15.53 059b (N = 27)
27) 13.98 0.43b (N = 32)
14) 17.43 0.41 (N = 20)
a Values are the means SEM.
Significantly different from group I, P < 0.05.
Table 6. Effect of breadsticks on serum phosphorus on dialysis
patients
Patient
Serum phosphorus, mg/dl
P04 binders Control Breadsticks
A
B
C
D
E
F
Mean SaM
6.00
3.80
6.50
5.20
6.68
5.16
5.59 0.45
7.27
5.05
7.03
5.20
10.60
8.63
7.30 0.86
P< 0.05
5.14
2.31
5.35
3.05
6.41
3.91
4.36 0.60
P <0.01
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Fig. 1. Metabolic balance study in a patient fed 1779 mg of phosphorus daily. The length of the balance was 32 days. The open bars
denote the amount of phosphorus excreted in the urine; the dashed bars, the amount of phosphorus excreted in the feces.
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Fig. 2. Mean results for four patients. The arrows indicate the
decrease in urinary phosphorus and the increase in phosphorus
excreted in the feces after the administration of breadsticks or
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Fig. 3. Increment in serum phosphorus from baseline levels dur-
ing the administration of phosphorus, 30 mg/kg, given alone
(control, .—.),phosphorus plus breadsticks containing Basal-
jel® (x---x), and phosphorus plus breadsticks containing Con-
trophosTM (o—o)
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total oral load. The only statistically significant
change from control was observed when the Con-
trophos gel was given.
Discussion
The results of this and previous studies [6] in-
dicate that a gel can be prepared that maintains a
high phosphorus-binding capacity, even when des-
sicated, if it is formed at the proper pH. This prop-
erty makes it possible to bake the gel in breadsticks
or other food. Strict balance studies in humans us-
ing the gel incorporated into breadsticks indicate
that in this form it is equally effective as Basaljel on
a dry weight basis. The in vivo dog studies indicate
that Basaljel retains very little phosphorus-binding
capacity after it is baked into breadsticks. This new
gel may provide an alternate therapeutic approach
for patients who refuse or cannot tolerate existing
preparations. Because there appears to be a good
correlation between the decrease in urinary phos-
phorus content and the increase in fecal phosphorus
content in all patients studied, individual adjust-
ments may be made by monitoring the change in
urinary phosphorus content. Obviously, measure-
ments of serum phosphorus concentrations are of
utmost importance and hypophosphatemia should
be avoided because there is a risk of producing
phosphate depletion and osteomalacia [14, 15].
Even though these studies indicate that this gel is
highly effective in binding phosphorus, the benefi-
cial effects of any medication must be weighed
against its potential side effects and/or toxicity.
Aluminum-containing gels have been used safely in
large quantities over long periods of time, and this
record suggests that these compounds are relatively
nontoxic. Aifrey et al have described, however, a
fatal encephalopathic syndrome in dialysis patients
who had high concentrations of aluminum in their
brains [9]. These data do not necessarily prove a
cause and effect relationship between the encepha-
lopathy and the concentrations of brain aluminum.
Nevertheless, it is an important observation and
one that has increased our concern about the poten-
tial toxicity of aluminum. The possible risk of devel-
oping this syndrome in patients receiving any alumi-
num-containing gel should be kept in mind, and this
risk must be weighed against the potential benefit of
adequate control of hyperphosphatemia. It will
seem, however, that the main source of aluminum
entering the body of uremic patients is not the
aluminum ingested in the diet but the aluminum
contamination of dialysis water [16, 17]. A potential
explanation has been provided by the demonstra-
tion of aluminum transfer during dialysis [11]. Be-
cause apparently parathyroid hormone may influ-
ence the intestinal absorption and tissue distribu-
tion of aluminum [18], amelioration of secondary
hyperparathyroidism by controlling hyperphospha-
temia may also be beneficial to the patient.
The present studies demonstrate that there is no
significant accumulation of aluminum in the brain of
normal or uremic rats following the oral administra-
tion of large quantities of Controphos. In spite of
this finding, there was a significant decrease in renal
cortical oxygen consumption. Berlyne et al [8] re-
ported a decrease in liver oxygen consumption in
rats treated with aluminum salts and suggested that
this was a manifestation of aluminum toxicity. The
data from the present study suggests that the de-
creased oxygen consumption of renal cortical slices
was not due to an accumulation of aluminum within
the tissues and could be overcome by the adminis-
tration of extra phosphorus in the diet (group IV,
Table 5). Long-term studies in humans are neces-
sary to determine the degree of aluminum retention
secondary to the ingestion of Controphos.
The new gel preparation may offer another ap-
proach to the control of phosphorus homeostasis in
patients with renal failure who refuse to take exist-
ing preparations.
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